Loading...
Market
Will the FDA approve ponsegromab for cancer cachexia by September 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA's official website or press release
Story
Pfizer's Ponsegromab Shows Promise in Phase 2 Study for Cancer Cachexia at ESMO24
Sep 14, 2024, 12:48 PM
Pfizer presented positive data from a Phase 2 study of its experimental drug, ponsegromab, at the ESMO24 conference. The drug showed promising results in treating cancer cachexia, a life-threatening condition characterized by severe weight loss and muscle wasting, which currently has no FDA-approved treatments. The study demonstrated that ponsegromab increased weight, improved appetite, and allowed patients to increase their physical activity. This development offers fresh hope for cancer patients suffering from this debilitating condition.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
